8-K - Fortress Biotech, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Fortress Biotech's majority-owned subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds.

Key Takeaways

1Cyprium sold PRV for $205 million gross proceeds on March 30, 2026.

2Fortress owns 80.4% of Cyprium's common stock on as-converted basis.

3Fortress expects at least $100 million from future dividends and intercompany agreements.

4Cyprium redeemed all 9.375% Perpetual Preferred Stock.

5Cyprium must pay 20% of PRV proceeds to NIH institute.

6PRV issued upon FDA approval of ZYCUBO® on January 12, 2026.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events.** On March 30, 2026, Fortress Biotech, Inc. (the “ **Company** ”) issued a press release announcing the closing of the sale by Cyprium Therapeut

Other Event

$205.0M$100.0M

9.01

.** **Financial Statements and Exhibits****.** (d) Exhibits. The following exhibits are filed herewith: | 99 | | | |---|---|---| | Exhibit Number | | De

Exhibits Only

Source Document

Exhibits (2)

8-K

EX-99